Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea · Delayed Price · Currency is KRW 1,218.00
+17.00 (1.42%)
Jul 1, 2026, 1:09 PM KST
Xcell Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,641 | 1,949 | 1,934 | 1,124 | 1,020 | 1,966 |
Other Revenue | - | - | - | - | 0 | - |
| 2,641 | 1,949 | 1,934 | 1,124 | 1,020 | 1,966 | |
Revenue Growth (YoY) | 51.56% | 0.76% | 72.11% | 10.18% | -48.12% | 264.00% |
Cost of Revenue | 4,350 | 3,915 | 3,333 | 2,987 | 2,773 | 2,284 |
Gross Profit | -1,710 | -1,966 | -1,399 | -1,863 | -1,753 | -318.08 |
Selling, General & Admin | 5,568 | 5,463 | 4,323 | 3,400 | 3,219 | 3,058 |
Research & Development | 3,180 | 2,576 | 2,728 | 2,753 | 2,596 | 1,832 |
Amortization of Goodwill & Intangibles | 111.1 | 108.25 | 53.23 | 53.83 | 73.48 | 56.2 |
Other Operating Expenses | 49.23 | 38.81 | 36.01 | 71.45 | 140.21 | 78.1 |
Operating Expenses | 9,498 | 8,886 | 7,931 | 7,076 | 6,546 | 5,387 |
Operating Income | -11,207 | -10,852 | -9,330 | -8,939 | -8,299 | -5,705 |
Interest Expense | -2.89 | -3.43 | -4.4 | -3.12 | -2.89 | -179.78 |
Interest & Investment Income | 130.25 | 116.56 | 201.29 | 50.84 | 114.02 | 41.75 |
Earnings From Equity Investments | -1.14 | -0.81 | - | - | - | - |
Currency Exchange Gain (Loss) | 10.8 | -0.57 | 12.84 | 2.52 | 11.57 | 2.38 |
Other Non Operating Income (Expenses) | -334.52 | -304.76 | -295.6 | -257.58 | -165.59 | -3,186 |
EBT Excluding Unusual Items | -11,405 | -11,045 | -9,416 | -9,147 | -8,342 | -9,026 |
Gain (Loss) on Sale of Investments | - | 19.02 | 2.72 | -0.87 | - | - |
Gain (Loss) on Sale of Assets | 98.66 | 98.66 | -130.13 | 21 | -0.53 | -12 |
Asset Writedown | - | - | - | -154.12 | - | - |
Pretax Income | -11,306 | -10,927 | -9,543 | -9,281 | -8,342 | -9,038 |
Net Income | -11,306 | -10,927 | -9,543 | -9,281 | -8,342 | -9,038 |
Net Income to Common | -11,306 | -10,927 | -9,543 | -9,281 | -8,342 | -9,038 |
Shares Outstanding (Basic) | 13 | 12 | 10 | 9 | 9 | 8 |
Shares Outstanding (Diluted) | 13 | 12 | 10 | 9 | 9 | 8 |
Shares Change (YoY) | 26.67% | 16.45% | 13.14% | 1.02% | 5.71% | 364.87% |
EPS (Basic) | -853.98 | -937.79 | -953.76 | -1049.40 | -952.90 | -1091.40 |
EPS (Diluted) | -854.17 | -938.00 | -954.00 | -1049.40 | -953.00 | -1091.40 |
Free Cash Flow | -10,829 | -10,369 | -7,379 | -7,008 | -8,475 | -5,952 |
Free Cash Flow Per Share | -817.91 | -889.87 | -737.48 | -792.48 | -968.02 | -718.67 |
Gross Margin | -64.74% | -100.87% | -72.30% | -165.77% | -171.89% | -16.18% |
Operating Margin | -424.39% | -556.79% | -482.33% | -795.37% | -813.59% | -290.14% |
Profit Margin | -428.13% | -560.65% | -493.36% | -825.74% | -817.85% | -459.67% |
Free Cash Flow Margin | -410.05% | -532.01% | -381.48% | -623.58% | -830.82% | -302.69% |
EBITDA | -9,542 | -9,148 | -7,677 | -7,341 | -6,786 | -4,686 |
EBITDA Margin | - | - | - | - | - | -238.34% |
D&A For EBITDA | 1,665 | 1,704 | 1,653 | 1,598 | 1,513 | 1,019 |
EBIT | -11,207 | -10,852 | -9,330 | -8,939 | -8,299 | -5,705 |
EBIT Margin | - | - | - | - | - | -290.14% |
Advertising Expenses | - | 315.64 | 154.72 | 315.24 | 267.87 | 279.25 |